SMARCA5, through the interaction with CTCF in leukemic cells, actively inhibits expression of the SPI1/PU.1 gene [7] that represents key hematopoietic transcription factor and dose-dependent leukemia suppressor [20]. The gene discussed is SPI1; the disease is leukemia.